IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of IPH 2101. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of IPH 2101. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of IPH 2101. |
| Estrone | Estrone may increase the thrombogenic activities of IPH 2101. |
| Estradiol | Estradiol may increase the thrombogenic activities of IPH 2101. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of IPH 2101. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of IPH 2101. |
| Mestranol | Mestranol may increase the thrombogenic activities of IPH 2101. |
| Estriol | Estriol may increase the thrombogenic activities of IPH 2101. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of IPH 2101. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of IPH 2101. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of IPH 2101. |
| Tibolone | Tibolone may increase the thrombogenic activities of IPH 2101. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of IPH 2101. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IPH 2101. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of IPH 2101. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of IPH 2101. |
| Zeranol | Zeranol may increase the thrombogenic activities of IPH 2101. |
| Equol | Equol may increase the thrombogenic activities of IPH 2101. |
| Promestriene | Promestriene may increase the thrombogenic activities of IPH 2101. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of IPH 2101. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of IPH 2101. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of IPH 2101. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of IPH 2101. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of IPH 2101. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of IPH 2101. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of IPH 2101. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of IPH 2101. |
| Formononetin | Formononetin may increase the thrombogenic activities of IPH 2101. |
| Estetrol | Estetrol may increase the thrombogenic activities of IPH 2101. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with IPH 2101. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IPH 2101. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with IPH 2101. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with IPH 2101. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with IPH 2101. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IPH 2101. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IPH 2101. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with IPH 2101. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with IPH 2101. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with IPH 2101. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with IPH 2101. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with IPH 2101. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IPH 2101. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IPH 2101. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with IPH 2101. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IPH 2101. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IPH 2101. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with IPH 2101. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IPH 2101. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with IPH 2101. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with IPH 2101. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with IPH 2101. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with IPH 2101. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IPH 2101. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with IPH 2101. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with IPH 2101. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with IPH 2101. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with IPH 2101. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with IPH 2101. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with IPH 2101. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with IPH 2101. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with IPH 2101. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with IPH 2101. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with IPH 2101. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with IPH 2101. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with IPH 2101. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with IPH 2101. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with IPH 2101. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with IPH 2101. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with IPH 2101. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with IPH 2101. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with IPH 2101. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with IPH 2101. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with IPH 2101. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with IPH 2101. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with IPH 2101. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with IPH 2101. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with IPH 2101. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with IPH 2101. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with IPH 2101. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with IPH 2101. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with IPH 2101. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with IPH 2101. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with IPH 2101. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with IPH 2101. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with IPH 2101. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with IPH 2101. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with IPH 2101. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with IPH 2101. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with IPH 2101. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with IPH 2101. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with IPH 2101. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with IPH 2101. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Canakinumab. |